Abstract:The modern healthcare system faces an unrelenting threat from microorganisms, as evidenced by global outbreaks of new viral diseases, emerging antimicrobial resistance, and the rising incidence of healthcare-associated infections (HAIs). An effective response to these threats requires rapid and accurate diagnostic tests that can identify causative pathogens at the point of care (POC). Such tests could eliminate diagnostic uncertainties, facilitating patient triaging, minimizing the empiric use of antimicrobial drugs, and enabling targeted treatments. Current standard methods, however, often fail to meet the needs of rapid diagnosis in POC settings. Culture-based assays entail long processing times and require specialized laboratory infrastructure; nucleic acid (NA) tests are often limited to centralized hospitals due to assay complexity and high costs. Here we discuss two new POC tests developed in our groups to enable the rapid diagnosis of infection. The first is nanoPCR that takes advantages of core-shell magnetoplasmonic nanoparticles (MPNs): (i) Au shell significantly accelerates thermocycling via volumetric, plasmonic light-to-heat conversion and (ii) a magnetic core enables sensitive in situ fluorescent detection via magnetic clearing. By adopting a Ferris wheel module, the system expedites multisamples in parallel with a minimal setup. When applied to COVID-19 diagnosis, nanoPCR detected SARS-CoV-2 RNA down to 3.2 copy/μL within 17 min. In particular, nanoPCR diagnostics accurately identified COVID-19 cases in clinical samples (n = 150), validating its clinical applicability. The second is a polarization anisotropy diagnostic (PAD) system that exploits the principle of fluorescence polarization (FP) as a detection modality. Fluorescent probes were designed to alter their molecular weight upon recognizing target NAs. This event modulates the probes' tumbling rate (Brownian motion), which leads to changes in FP. The approach is robust against environmental noise and benefits from the ratiometric nature of the signal readout. We applied PAD to detect clinically relevant HAI bacteria (Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus). The PAD assay demonstrated detection sensitivity down to the single bacterium level and determined both drug resistance and virulence status. In summary, these new tests have the potential to become powerful tools for rapid diagnosis in the infectious disease space. They do not require highly skilled personnel or labor-intensive analyses, and the assays are quick and cost-effective. These attributes will make nanoPCR and PAD well-aligned with a POC workflow to aid physicians to initiate prompt and informed patient treatment.

Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line?

Point-Of-Care or Point-Of-Need Diagnostic Tests: Time to Change Outbreak Investigation and Pathogen Detection

A review of the value of point-of-care testing for community-acquired pneumonia

Point-of-care diagnostics for respiratory viral infections

[Recent Advances in Molecular Point of Care Tests]

An overview of point-of-care testing for infections in critically ill patients

The impact of digital technologies on point-of-care diagnostics in resource-limited settings

Opportunities and challenges of point of care testing paradigms in the post-COVID era

Analysis and mapping of global research publications on point‐of‐care testing for infectious diseases

Utilizing Point-of-Care Testing to Optimize Patient Care

Recent advances in point-of-care testing of COVID-19

Rational clinical use of near-patient analytical systems for molecular detection of infectious agents

Development of Integrated Systems for On-Site Infection Detection

Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology

The Adoption of Point of Care Testing Technologies for Respiratory Tract Infections in Primary Care in Australia: Challenges and Facilitators

Point-of-care testing: state-of-the art and perspectives

Evidence-based point-of-care diagnostics: current status and emerging technologies

Deployment of COVID-19 diagnostic testing: challenges and key considerations for the future

The impact of commercial rapid respiratory virus diagnostic tests on patient outcomes and health system utilization

Barriers to implementation of rapid identification and antimicrobial susceptibility testing technologies in the clinical microbiology laboratory: an American perspective

Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) – does it leverage any advantage in clinical decision making?